Lysophosphatidic acid (Oleyl form) |
Catalog No.GB40270
One-Click Copy Product Info
|
Lysophosphatidic acid (Oleyl form)은 세포 신호 전달과 다양한 생물학적 과정에서 중요한 역할을 하는 생물학적으로 활성 지질이다. Lysophosphatidic acid은 Lysophosphatidic acid(LPA) 수용체의 작용제로 작용해서 세포 성장, 이동 및 기타 세포 기능에 영향을 미친다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 22556-62-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lysophosphatidic acid (Oleyl form)은 세포 신호 전달과 다양한 생물학적 과정에서 중요한 역할을 하는 생물학적으로 활성 지질이다. Lysophosphatidic acid은 Lysophosphatidic acid(LPA) 수용체의 작용제로 작용해서 세포 성장, 이동 및 기타 세포 기능에 영향을 미친다. Lysophosphatidic acid은 인산 또는 환상 인산 머리 그룹(환상 인산이라고 함), 글리세롤 골격 그리고 지방산 또는 지방 알코올 사슬로 구성된 단순한 지질 분자이다 [3]. 게다가 Lysophosphatidic acid은 과립체 증식 활성화 수용체 γ(PPARγ)의 직접적인 작용제이다 [4]. Lysophosphatidic acid은 염증, 혈전 형성, 동맥 경화증을 일으킬 수 있다 [5]. Lysophosphatidic acid은 BV-2와 원핵 쥐 미세아교세포의 M1 유사 현상형으로의 분극을 촉진할 수 있다 [6]. 복강 주사된 Lysophosphatidic acid은 쥐에서 아세트아미노펜(APAP)에 의해 유도된 급성 간 손상을 현저하게 줄일 수 있다 [7].
References:
[1] Tigyi G, Parrill A L. Molecular mechanisms of lysophosphatidic acid action[J]. Progress in lipid research, 2003, 42(6): 498-526.
[2] Moolenaar W H. Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger[J]. Journal of Biological Chemistry, 1995, 270(22): 12949-12952.
[3] Liu W, Hopkins A M, Hou J. The development of modulators for lysophosphatidic acid receptors: A comprehensive review[J]. Bioorganic chemistry, 2021, 117: 105386.
[4] Geraldo L H M, Spohr T C L S, Amaral R F, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies[J]. Signal transduction and targeted therapy, 2021, 6(1): 45.
[5] Zhou Y, Little P J, Ta H T, et al. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease[J]. Pharmacology & Therapeutics, 2019, 204: 107404.
[6] Plastira I, Bernhart E, Goeritzer M, et al. 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype[J]. Journal of neuroinflammation, 2016, 13: 1-18.
[7] Bae G H, Lee S K, Kim H S, et al. Lysophosphatidic acid protects against acetaminophen-induced acute liver injury[J]. Experimental & molecular medicine, 2017, 49(12): e407-e407.
| Cas No. | 22556-62-3 | SDF | |
| Formula | C21H41O7P·xNa+ | M.Wt | 436.52 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2908 mL | 11.4542 mL | 22.9085 mL |
| 5 mM | 458.2 μL | 2.2908 mL | 4.5817 mL |
| 10 mM | 229.1 μL | 1.1454 mL | 2.2908 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)